News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
873,355 Results
Type
Article (88183)
Company Profile (825)
Press Release (784327)
Multimedia
Podcasts (206)
Webinars (32)
Section
Business (233349)
Career Advice (4152)
Deals (39895)
Drug Delivery (156)
Drug Development (91477)
Employer Resources (205)
FDA (18438)
Job Trends (17440)
News (398128)
Policy (39996)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3023)
Academic (2)
Accelerated approval (41)
Adcomms (36)
Allergies (164)
Alliances (56982)
ALS (191)
Alzheimer's disease (1826)
Antibody-drug conjugate (ADC) (378)
Approvals (18639)
Artificial intelligence (682)
Autoimmune disease (199)
Automation (48)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (212)
Biotechnology (490)
Bladder cancer (176)
Brain cancer (69)
Breast cancer (695)
Cancer (5340)
Cardiovascular disease (474)
Career advice (3578)
Career pathing (43)
CAR-T (318)
CDC (68)
Celiac Disease (2)
Cell therapy (877)
Cervical cancer (40)
Clinical research (77410)
Collaboration (1953)
Company closure (5)
Compensation (1232)
Complete response letters (82)
COVID-19 (3004)
CRISPR (110)
C-suite (968)
Cystic fibrosis (157)
Data (6687)
Decentralized trials (2)
Denatured (76)
Depression (162)
Diabetes (555)
Diagnostics (7326)
Digital health (54)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (329)
Drug pricing (230)
Drug shortages (36)
Duchenne muscular dystrophy (258)
Earnings (100734)
Editorial (69)
Employer branding (25)
Employer resources (174)
Events (135860)
Executive appointments (1071)
FDA (21811)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (26)
Funding (1640)
Gene editing (233)
Generative AI (71)
Gene therapy (719)
GLP-1 (1169)
Government (5482)
Grass and pollen (8)
Guidances (389)
Healthcare (20983)
HIV (76)
Huntington's disease (54)
IgA nephropathy (90)
Immunology and inflammation (310)
Immuno-oncology (76)
Indications (134)
Infectious disease (3321)
Inflammatory bowel disease (218)
Inflation Reduction Act (17)
Influenza (134)
Intellectual property (268)
Interviews (817)
IPO (17971)
IRA (61)
Job creations (5202)
Job search strategy (2867)
JPM (73)
Kidney cancer (20)
Labor market (98)
Layoffs (663)
Leadership (44)
Legal (10166)
Liver cancer (102)
Longevity (19)
Lung cancer (717)
Lymphoma (396)
Machine learning (49)
Management (66)
Manufacturing (921)
MASH (184)
Medical device (15093)
Medtech (15159)
Mergers & acquisitions (23044)
Metabolic disorders (1481)
mRNA (201)
Multiple sclerosis (179)
NASH (23)
Neurodegenerative disease (386)
Neuropsychiatric disorders (108)
Neuroscience (3247)
Neurotech (1)
NextGen: Class of 2026 (7710)
Non-profit (5122)
Now hiring (70)
Obesity (723)
Opinion (348)
Ovarian cancer (175)
Pain (230)
Pancreatic cancer (252)
Parkinson's disease (317)
Partnered (39)
Patents (546)
Patient recruitment (553)
Peanut (65)
People (67158)
Pharmaceutical (145)
Pharmacy benefit managers (34)
Phase 1 (23917)
Phase 2 (33587)
Phase 3 (25310)
Pipeline (6099)
Policy (358)
Postmarket research (3554)
Preclinical (10725)
Press Release (72)
Prostate cancer (273)
Psychedelics (60)
Radiopharmaceuticals (318)
Rare diseases (1018)
Real estate (7445)
Recruiting (81)
Regulatory (29355)
Reports (69)
Research institute (2744)
Resumes & cover letters (653)
Rett syndrome (31)
RNA editing (21)
RSV (90)
Schizophrenia (165)
Series A (278)
Series B (206)
Service/supplier (30)
Sickle cell disease (110)
Special edition (29)
Spinal muscular atrophy (179)
Sponsored (49)
Startups (4340)
State (2)
Stomach cancer (21)
Supply chain (117)
Tariffs (101)
The Weekly (128)
Vaccines (1192)
Venture capital (102)
Weight loss (495)
Women's health (105)
Worklife (23)
Date
Today (179)
Last 7 days (934)
Last 30 days (3231)
Last 365 days (32904)
2026 (5668)
2025 (33228)
2024 (38141)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1290)
Alabama (95)
Alaska (7)
Arizona (355)
Arkansas (15)
Asia (51695)
Australia (9084)
California (12196)
Canada (3469)
China (1232)
Colorado (515)
Connecticut (533)
Delaware (362)
Europe (118950)
Florida (1813)
Georgia (396)
Hawaii (4)
Idaho (68)
Illinois (1020)
India (81)
Indiana (574)
Iowa (24)
Japan (469)
Kansas (135)
Kentucky (48)
Louisiana (34)
Maine (84)
Maryland (1518)
Massachusetts (8953)
Michigan (381)
Minnesota (687)
Mississippi (7)
Missouri (145)
Montana (36)
Nebraska (30)
Nevada (134)
New Hampshire (88)
New Jersey (3277)
New Mexico (33)
New York (3216)
North Carolina (1686)
North Dakota (10)
Northern California (5900)
Ohio (377)
Oklahoma (23)
Oregon (55)
Pennsylvania (2430)
Puerto Rico (25)
Rhode Island (52)
South America (1665)
South Carolina (70)
South Dakota (1)
Southern California (4724)
Tennessee (192)
Texas (1918)
United States (43906)
Utah (369)
Vermont (1)
Virginia (308)
Washington D.C. (88)
Washington State (1010)
West Virginia (4)
Wisconsin (138)
Wyoming (2)
There are 873,355 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Venture capital
After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar
Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million raised to date, including a $45 million series A extension that closed Tuesday.
March 3, 2026
·
3 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
This webinar explores how collaborative-initiated trials and Investigator-Initiated Trials (IITs) are complementing traditional drug development to accelerate innovation, advance precision medicine, and address clinically meaningful questions.
March 3, 2026
·
1 min read
·
BioSpace Insights
Press Releases
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
March 3, 2026
·
4 min read
Press Releases
Hubly Surgical awarded Breakthrough Technology Designation for Neurosurgical Products with Premier, Inc.
March 3, 2026
·
2 min read
Press Releases
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
March 3, 2026
·
6 min read
Press Releases
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
March 3, 2026
·
10 min read
Press Releases
Acumen Pharmaceuticals to Showcase Advances in Alzheimer’s Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
March 3, 2026
·
7 min read
Press Releases
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
March 3, 2026
·
4 min read
Press Releases
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
March 3, 2026
·
6 min read
Press Releases
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
March 3, 2026
·
4 min read
1 of 87,336
Next
